Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Reading the DNA Fingerprints of Prostate Cancer September 12, 2026
- Phase 1/2 Trial Results for Tinengotinib (TT-00420) in mCRPC September 12, 2026
- STAMINA: Supervised Exercise and Dietary Advice Cut ADT-Related Decline in Prostate Cancer September 8, 2026
- Dietary Fat and Survival After Nonmetastatic Prostate Cancer September 7, 2026
CRISPR is Here to Stay: Gene Therapy Succesfully Used On An Infant With Incurable Disease
/in Not PCa related/by MaxTargeting the Undruggable: SCORT–Cas13d Nanotherapy Against Metastatic Prostate Cancer
/in CRISPR, Preclinical Research/by MaxUTRxM1-18: mRNA Drug Targeting c-MYC Offers New Hope for Prostate Cancer Patients
/in mRNA, Preclinical Research/by MaxPenetrium: A Breakthrough in Overcoming Cold Tumors and Metastatic Cancer
/in Preclinical Research/by MaxPioglitazone: Diabetes Drug Shows Promise for Treating Prostate Cancer
/in Drug repurposing, Preclinical Research/by MaxUPDATE: JANX007 Starts Phase 1b Expansion Studies
/in Clinical Trial, Metastatic, Phase 1/by MaxNTS071 to Target p53 Y220C Mutation in Solid Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxA New Insight From the ARANOTE Trial for mHSPC
/in Post-hoc/by Max